| 1 |
GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [J]. Lancet Gastroenterol Hepatol, 2020, 5(3): 245-266.
|
| 2 |
Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases [J]. Hepatology, 2017, 65(1): 310-335.
|
| 3 |
Reiberger T, Mandorfer M. Beta adrenergic blockade and decompensated cirrhosis [J]. J Hepatol, 2017, 66(4): 849-859.
|
| 4 |
Tripathi D, Stanley AJ, Hayes PC, et al. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients [J]. Gut, 2015, 64(11): 1680-1704.
|
| 5 |
de Franchis R, Baveno Ⅵ Faculty. Expanding consensus in portal hypertension: report of the Baveno Ⅵ Consensus Workshop: Stratifying risk and individualizing care for portal hypertension [J]. J Hepatol, 2015, 63(3): 743-752.
|
| 6 |
中华医学会肝病学分会，中华医学会消化病学分会，中华医学会消化内镜学分会,等.肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J].中华内科杂志, 2016, 55(1): 57-72.
|
| 7 |
Shukla R, Kramer J, Cao Y, et al. Risk and predictors of variceal bleeding in cirrhosis patients receiving primary prophylaxis with non-selective beta-blockers [J]. Am J Gastroenterol, 2016, 111(12): 1778-1787.
|
| 8 |
Lv Y, Zuo L, Zhu X, et al. Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study [J]. Gut, 2019, 68(7): 1297-1310.
|
| 9 |
Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol [J]. Gut, 2013, 62(11): 1634-1641.
|
| 10 |
Zhang F, Xu H, Chen M, et al. Dose-dependent effect of propranolol on the hemodynamic response in cirrhotic patients with gastroesophageal varices [J]. Eur J Gastroenterol Hepatol, 2019, 31(3): 368-374.
|
| 11 |
李晶，孙东杰，王广川,等.卡维地洛与普萘洛尔降低肝硬化门静脉高压患者肝静脉压力梯度效果的对比分析[J].临床肝胆病杂志, 2016, 32(1): 114-118.
|
| 12 |
Zacharias AP, Jeyaraj R, Hobolth L, et al. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices [J]. Cochrane Database Syst Rev, 2018, 10(10): CD011510.
|
| 13 |
Villanueva C, Albillos A, Genescà J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial [J]. Lancet, 2019, 393(10181): 1597-1608.
|
| 14 |
Pfisterer N, Dexheimer C, Fuchs EM, et al. Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding [J]. Aliment Pharmacol Ther, 2018, 47(7): 966-979.
|
| 15 |
Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: Evidence-based indications and limitations [J]. JHEP Rep, 2020, 2(1): 100063.
|
| 16 |
中国门静脉高压诊断与监测研究组(CHESS)，中华医学会消化病学分会微创介入协作组，中国医师协会介入医师分会急诊介入专业委员会,等.中国肝静脉压力梯度临床应用专家共识(2018版) [J].中华消化杂志, 2018, 38(11): 728-738.
|
| 17 |
Kim TW, Kim HJ, Chon CU, et al. Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis? [J]. Clin Mol Hepatol, 2012, 18(2): 203-212.
|
| 18 |
Park JH, Jun DW, Choi J, et al. Low-dose propranolol as secondary prophylaxis for varix bleeding decreases mortality and rebleeding rate in patients with tense ascites [J]. J Clin Med, 2019, 8(5): 573.
|
| 19 |
Kockerling D, Nathwani R, Forlano R, et al. Current and future pharmacological therapies for managing cirrhosis and its complications [J]. World J Gastroenterol, 2019, 25(8): 888-908.
|
| 20 |
Tapper EB, Asrani SK. The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care [J]. J Hepatol, 2020, 73(2): 441-445.
|